IP Library Patent Application 17929978
Patent Application
App. No. 17/929,978

CLASS II, TYPE V CRISPR SYSTEMS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/929,978
Abstract

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful for gene editing.

Claims (25)

1 .- 164 . (canceled)

165 . An engineered nuclease system comprising:

(a) an endonuclease having at least 75% sequence identity to SEQ ID NO: 215 or a variant thereof; and

(b) an engineered guide ribonucleic acid (RNA), wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleic acid sequence.

166 . The engineered nuclease system of claim 165 , wherein said engineered guide RNA comprises a sequence with at least 80% sequence identity to the non-degenerate nucleotides of any one of SEQ ID NOs: 3471, 3539, 3551-3559, 3608-3610, 3612, 3636-3637, 3640-3641, 3644-3645, 3648-3649, 3652-3653, 3656-3657, 3660-3661, 3664-3667, 3671-3672, 3677-3678, 3695-3696, 3729-3730, 3734-3735, and 3851-3857.

167 . The engineered nuclease system of claim 165 , wherein said endonuclease is configured to bind to a protospacer adjacent motif (PAM) sequence comprising any one of SEQ ID NOs: 3863-3913.

168 . The engineered nuclease system of claim 165 , wherein said engineered guide RNA comprises a sequence complementary to a eukaryotic, fungal, plant, mammalian, or human genomic polynucleotide sequence.

169 . The engineered nuclease system of claim 165 , wherein said engineered guide RNA is 30-250 nucleotides in length.

170 . The engineered nuclease system of claim 165 , wherein said endonuclease comprises at least one of an S168R mutation, an E172R mutation, an N577R mutation, or a Y170R mutation when a sequence of said endonuclease is optimally aligned based on a pairwise alignment to SEQ ID NO: 215.

171 . The engineered nuclease system of claim 170 , wherein said endonuclease comprises said S168R mutation and said E172R mutation when a sequence of said endonuclease is optimally aligned based on a pairwise alignment to SEQ ID NO: 215.

172 . The engineered nuclease system of claim 170 , wherein said endonuclease comprises said N577R mutation or said Y170R mutation when a sequence of said endonuclease is optimally aligned based on a pairwise alignment to SEQ ID NO: 215.

173 . The engineered nuclease system of claim 170 , wherein said endonuclease comprises said S168R mutation when a sequence of said endonuclease is optimally aligned based on a pairwise alignment to SEQ ID NO: 215

174 . The engineered nuclease system of claim 165 , wherein said endonuclease does not comprise a mutation of E172, N577, or Y170.

175 . The engineered nuclease system of claim 165 , further comprising a single- or double-stranded deoxyribonucleic acid (DNA) repair template comprising from 5′ to 3′: a first homology arm comprising a sequence of at least 20 nucleotides 5′ to said target nucleic acid sequence, a synthetic DNA sequence of at least 10 nucleotides, and a second homology arm comprising a sequence of at least 20 nucleotides 3′ to said target sequence.

176 . The engineered nuclease system of claim 175 , wherein said first homology arm or said second homology arm comprises a sequence of at least 40 nucleotides.

177 . The engineered nuclease system of claim 175 , wherein said first homology arm or said second homology arm is homologous to a genomic sequence of a prokaryote, bacteria, fungus, or eukaryote.

178 . The engineered nuclease system of claim 175 , wherein said single- or double-stranded DNA repair template comprises a transgene donor.

179 . The engineered nuclease system of claim 165 , further comprising a deoxyribonucleic acid (DNA) repair template comprising a double-stranded DNA segment further comprising one single-stranded DNA segment or two single-stranded DNA segments flanking said double-stranded DNA segment.

180 . The engineered nuclease system of claim 179 , wherein said one single-stranded DNA segment or said two single-stranded DNA segments have a length from 4 to 10 nucleotide bases.

181 . The engineered nuclease system of claim 179 , wherein said double-stranded DNA segment comprises a barcode, an open reading frame, an enhancer, a promoter, a protein-coding sequence, a miRNA coding sequence, an RNA coding sequence, or a transgene.

182 . The engineered nuclease system of claim 179 , wherein said double-stranded DNA segment is flanked by a nuclease cut site.

183 . The engineered nuclease system of claim 165 , wherein said endonuclease comprises a sequence at least 80% identical to SEQ ID NO: 215 or a variant thereof.

184 . The engineered nuclease system of claim 165 , wherein said endonuclease comprises a sequence at least 90% identical to SEQ ID NO: 215 or a variant thereof.

185 . The engineered nuclease system of claim 165 , wherein said endonuclease comprises one or more nuclear localization sequences (NLSs) proximal to an N- or C-terminus of said endonuclease.

186 . The engineered nuclease system of claim 165 , wherein said endonuclease is a class II, type V Cas endonuclease.

Assignments (4)
CHANGE OF NAME Recorded Feb 6, 2026
From: METAGENOMI, INC.
To: METAGENOMI THERAPEUTICS, INC.
Reel/Frame 073717/0149 →
RELEASE OF SECURITY INTEREST Recorded Dec 12, 2025
From: CATALIO NEXUS FUND III, LP
To: AFFINI-T THERAPEUTICS, INC.
Reel/Frame 073201/0168 →
SECURITY INTEREST Recorded Mar 4, 2025
From: AFFINI-T THERAPEUTICS, INC.
To: CATALIO NEXUS FUND III, LP
Reel/Frame 070403/0862 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2022
From: THOMAS, BRIAN; BROWN, CHRISTOPHER; DEVOTO, AUDRA; BUTTERFIELD, CRISTINA; ALEXANDER, LISA; GOLTSMAN, DANIELA S.A.; ALBERS, JUSTINE B.; BROOKS, ALAN; COST, GREG; TEMOCHE-DIAZ, MORAYMA; CASTELLE, CINDY; LAMOTHE, REBECCA
To: METAGENOMI, INC.
Reel/Frame 061487/0965 →